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1014 ABSTRACTSand degranulate in, the lungs of RSV infected animals are
underway.
Future experiments designed to elucidate the physiologi-
cal importance of eosinophils in viral respiratory infections
are being performed in transgenic mice that are unable to
mount an eosinophil response to the infection. Because
RSV-induced MIP-1-a concentrations correlate with ribo-
nuclease activity and measurable ECP concentrations in
human infants with RSV bronchiolitis, we have begun to
evaluate RSV and PVM infection in transgenic mice with
targeted deletions in the MIP-1-a gene. Moreover, given the
importance of IL-5 in eosinophilopoiesis, we have designed
experiments to study the progression of PVM (and RSV)
infection in animals deficient in IL-5 production. Disease
progression and severity in these (and possibly other)
transgenic animals will elucidate whether the eosinophilic
response to viral infection is advantageous or detrimental
to the host. Our long-term goal is to translate what we learn
about eosinophil biology in the context of viral disease to
the development of potent immunomodulatory interven-
tions for related human infections.
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allergic inflammation involving eosinophils and basophils.
CLC protein, the unique autocrystallizing constituent that
forms these distinctive hexagonal bipyramidal crystals,
became synonymous with eosinophil lysophospholipase
(LPLase) when chromatographic purification of this enzy-
matic activity yielded protein preparations that formed
CLC and contained the CLC protein (1). However, our
cloning of the CLC cDNA revealed a polypeptide of
16?5 kD with 142 amino acids that bore no similarities to
any known sequences of LPLases, phospholipases or other
lipolytic enzymes, but that had some similarities to
members of the superfamily of S-type lactose-binding and
IgE-binding animal lectins (2). Our subsequent solution of
the X-ray crystallographic structure of CLC protein
showed that its overall tertiary fold was highly similar to
that of the prototype galectins (Gal) (3), members of the b-
galactoside binding animal lectin superfamily. The struc-
ture of CLC protein provided details of a carbohydrate
recognition domain (CRD) with both similarities to and
differences from other members of the galectin family.
These structural findings, the observation of apparently
weak anity for lactosamine-containing sugars (3,4), and a
conserved genomic structure comparable to other galectins
(5), provided compelling evidence that CLC should be
designated Galectin-10 (6), the 10th member of the
mammalian galectin family. Most recently, using X-ray
crystallographic approaches, we have demonstrated that
CLC protein does not have an anity for b-galactosides,
but instead binds mannose in a unique manner that is
different from the binding of lactosamine sugars by other
related galectins (7). A detailed analysis of the topology and
chemical nature of CLC protein’s CRD in complex with
mannose has provided the first picture of carbohydrate
recognition by this unique lectin. These findings are
providing new clues towards understanding the potential
intracellular and extracellular roles for CLC protein in
eosinophil and basophil biology and in inflammation.
The X-ray crystal structure of CLC protein at 1?8A˚, from
crystals identical in morphology to the crystals found in
vivo, showed that the protein has a ‘jelly-roll’ motif that
results from a tight association between a five-stranded and
a six-stranded b-sheet joined by two 310 helices at the two
ends (3). The overall structural fold of CLC protein is
highly similar to that of galectins-1, -2, and -3, but most
similar to Galectin-7 (8), while sharing only moderate
amino acid sequence identity (*20%) with members of the
galectin superfamily. CLC protein has a CRD containing
nine of the 13 conserved residues in the CRD of galectins-1,
-2, and -7, sharing six of eight residues directly involved in
b-galactoside binding by these galectins (3). This was
apparently borne out by carbohydrate binding studies using
solid-phased simple sugars (3,4); CLC protein was
reported to have specific, but weak, carbohydrate binding
activity for N-acetyl-D-glucosamine and lactose (3,4), but
the mode of carbohydrate binding was not established.
However, our recent studies clearly show that these weak
carbohydrate binding activities can be attributed to
Galectin-10 binding to the crossed-linked agarose (or
Sepharose) matrix and not to the solid-phased lactosa-Structural biology of Charcot–Leyden
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FIG. 1. X-ray crystallographic structure showing the
binding of mannose to the carbohydrate recognition
domain (CRD) of the Charcot–Leyden crystal (CLC)
protein/galectin-10. The interactions between mannose
and the CLC CRD are indicated and include ring stacking
interactions with Trp72, and three hydrogen bonds which
involve residues His53, Asn65 and Gln75 from three beta
strands (S4, S5, and S6B, respectively) of the protein, and
oxygen atoms O6, O1 and O2, respectively, from
mannose. Hydrogen bonds are represented by the strings
of small spheres.
ABSTRACTS 1015mine-containing simple sugars themselves (9). In addition
to the structural similarities between CLC protein and other
galectins, the intron–exon architecture of the CLC gene is
analogous to that of the galectins, with the CRD of CLC
protein encoded by a single exon (5). In light of these
observations, CLC protein was designated Galectin-10 (6).
However, the natural carbohydrate-containing ligand of
CLC protein has not as yet been identified, and the
predicted bifunctional role of CLC protein as both galectin
and LPLase in eosinophil-mediated inflammatory re-
sponses has remained highly speculative. At the cellular
level, CLC protein is localized to a number of subcellular
compartments in eosinophils and basophils. These include a
residual primary granule population, agranular spaces in
the cytosol beneath the plasma membrane, and the nucleus
of the eosinophil, and in basophils in the histamine-
containing granule population. Following activation and
degranulation of basophils by f-met peptide, CLC protein
relocalizes from the histamine-containing granules to the
plasma membrane, but resumes its granule localization by
endocytosis and vesicular transport during basophil recov-
ery (10). These findings implicate CLC protein in the
degranulation and recovery of basophils. The protein is
also localized to the nucleus during basophil activation and
degranulation. Although a role for CLC protein in the
nucleus of the basophil or eosinophil remains highly
speculative, we have suggested that it could play a role in
RNA processing, a possibility suggested by findings that
both Galectin-1 and -3 have activities in pre-mRNA
splicing. The sequence and structural similarities between
CLC protein and the lectin domain of Galectin-3, also
suggest that CLC protein could be involved in eosinophil or
basophil interactions with the oligosaccharides of extra-
cellular matrix substrates.
The CLC protein is considered to be eosinophil
LPLase despite the lack of apparent sequence or structural
homology with any other LPLases. The protein was
originally reported to exhibit divalent cation-independent
weak LPLase activity with a Michaelis constant (Km) of
22 mM and Vmax of 50 nmol
71 hmg71 at 378C for lysopal-
mitoylphosphatidylcholine substrate (1). The crystal struc-
ture of CLC protein in the absence of bound substrate or
ligand did not provide direct information about the
location of an LPLase active site. Nevertheless, we
identified a putative active site some 15A˚ away from
the CRD on the opposite face of the molecule (3). However,
the nature and mechanism of LPLase activity for CLC
protein remains highly speculative. As noted above, CLC
protein shows no sequence similarities to any known
LPLases or other lipolytic enzymes (2), but has moderate
amino acid sequence identity and near structural identity to
the galectins (3). The Galectin-10 amino acid sequence is
most similar to Galectin-3 and Galectin-4 (25–30%) and
less similar to Galectin-1 and Galectin-2 (15–20%) (3). The
BESTFIT algorithm gives similarities of 43–48% for
Galectins-1, -2, -3 and -7 (4). Based on these observations,
we have reassessed the LPLase activity of Galectin-10,
utilizing antibody anity chromatography to completely
deplete eosinophil lysates of CLC protein as determined by
highly sensitive Western blotting and CLC radioimmu-noassay techniques (11). The CLC-depleted eosinophil
lysates retained 100% of their LPLase activity, and this
activity was fully blocked by the previously reported
sulphydryl-reactive eosinophil LPLase inhibitors, n-ethyl-
maleimide (NEM) and p-chloromercuribenzene sulphonate
(pCMBS) (1). In contrast, anity-purified homogeneous
CLC from the same separations lacked significant
LPLase activity, and any residual activity was entirely
insensitive to inhibition by NEM or pCMBS. Moreover,
recombinant Galectin-10, produced and anity purified
from Escherichea coli using the pFLAG-CTC vector
system, did not express any LPLase activity. X-ray
crystallographic structures of native CLC soaked or
co-crystallized with pCMBS or NEM, showed that pCMBS
bound to Cys29 and Cys57 near the CRD. In contrast,
NEM bound in the Galectin-10 CRD, via ring stacking
interactions with Trp72, in a manner analogous to mannose
binding in the Galectin-10 CRD (Fig. 1) (7). Our results
show that Galectin-10 is not a dual function galectin/
1016 ABSTRACTSLPLase, but nevertheless it interacts with known inhibitors
of eosinophil LPLase via amino acid residues in its CRD.
The enzyme responsible for human eosinophil LPLase
activity remains to be been defined, but may be similar to
pancreatic LPLase (12).
The galectins comprise a growing family of animal lectins
which possess at least one CRD, and exhibit some sequence
conservation (13). Members of this family show a wide-
spread distribution across genus and species, ranging from
sponges to humans, and have been implicated in intra- and
extracellular functions such as cell–cell and cell–matrix
interactions through glycoconjugate-mediated recognition.
To date, 10 mammalian galectins including CLC protein
have been identified, as well as many from other genera and
species (6). Galectins 7 and 10 are the only monomeric
members of the galectin family for which crystal structures
have been determined (3,8). As noted above, the overall
structural fold of Galectin-10 is highly similar to that of
Galectin-7. However, their CRDs are quite different with
only nine out of the 13 residues which comprise the CRD
conserved between these two galectins. These differences
cause significant changes both in the topology and chemical
nature of their CRDs, and have implications for both their
carbohydrate ligand specificities and precise biological
function(s). The crystal liganded structures of Galectin-7
and Galectin-10 have provided new insights into the
multivalent functionality of the galectin family in carbohy-
drate recognition. In particular, Galectin-7 binds lacto-
samine-containing simple saccharides but not mannose in
the crystal, in marked contrast to Galectin-10 (CLC
protein) which fails to bind lactosamine-containing sugars,
but instead binds mannose via a different structural
mechanism (Fig. 1) (7). The ability of CLC protein to bind
mannose draws attention to the functional activities of the
family of mannose-binding proteins. These proteins are
generally C-type lectins, which include serum mannose-
binding proteins and pulmonary surfactant apoproteins A
and D. Mannose-binding proteins play a role in antibody-
independent host defense against pathogens by binding
avidly to carbohydrate structures on foreign cell surfaces
and inducing opsonization and complement-mediated cell
lysis. Although CLC protein shares no apparent sequence
homology with the mannose-binding proteins, it could play
a similar role in eosinophil effector or inflammatory
responses to multicellular (helminth) parasites. Although
we have shown that CLC protein binds mannose, the
natural glycoconjugate ligand of the protein has yet to be
identified. Our results provide a starting point in the search
for the biologically relevant ligand(s) of CLC protein, as
well as in providing clues to its functional role(s) in
eosinophils and basophils.
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The use of eosinophil granule proteins as markers of
eosinophil activity and turnover in human disease was
suggested in the mid 1970s. The commercialization of
immuno-assays to measure one of these proteins, i.e. ECP
(eosinophil cationic protein), has made this a common tool
in research and as a clinical tool in the monitoring
of certain patients with asthma, atopic dermatitis, food
allergy etc.
The eosinophil markers have been measured in most
body fluids as reflections of the activity of the eosinophils in
the local process or as reflections of systemic activation of
the cells (1). Measurements in local fluids involve the
cerebrospinal fluid in patients with various neurological
disorders. Thus, highly raised levels of ECP were observed
in patients with bacterial meningitis (2), but also to some
extent in viral encephalitis and in multiple sclerosis
indicating the involvement of the eosinophils in the
inflammatory processes in these diseases. The levels in
bacterial meningitis were of particular interest, since the
highest levels were found in those patients who had a poor
outcome of their disease. The levels were in fact well above
or equal to the levels needed to induce permanent
neurological damage in experimental animals (3). The
measurements were performed in nasal washings in
patients with nasal disorders, in particular in rhinitis, but
also as tools to monitor environmental influences
